Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain.
Pharmacoecon Open
; 3(2): 229-235, 2019 Jun.
Article
en En
| MEDLINE
| ID: mdl-30324566
ABSTRACT
BACKGROUND:
Philadelphia chromosome-negative (Ph-) relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL) is rare, and information on its impact on healthcare systems is scarce.OBJECTIVE:
To quantify the time and reimbursement associated with hospitalisations of patients with R/R ALL in a Spanish hospital.METHODS:
Retrospective review of medical charts identified patients aged ≥ 18 years with Ph- R/R ALL hospitalised between 1998 and 2014. Data were collected from the date of first diagnosis of R/R ALL (index) until death or loss to follow-up. The primary endpoint was the proportion of time hospitalised during chemotherapy. Reimbursement associated with hospitalisations (including associated chemotherapy) was also assessed.RESULTS:
Thirty-two patients were eligible for inclusion. Their median age was 41 years, and 50% had a first remission duration of ≤ 1 year; 34% had undergone allogeneic haematological stem-cell transplantation (alloHSCT). Overall, 31 patients had received intensive salvage chemotherapy, during which there were 42 hospitalisations (mean 1.4/patient; mean duration 26 days). Patients spent a mean of 71% of the chemotherapy period in hospital. Total mean reimbursement was 26,417 per patient, almost all (25,723) attributable to inpatient stays (18,986/hospitalisation). From the index date to death or loss to follow-up (excluding alloHSCT-related hospitalisations), there were 80 hospitalisations (mean duration 24 days); mean reimbursement was 16,692 per hospitalisation and 41,730 per patient. AlloHSCT (n = 8) involved 18 hospitalisations (mean reimbursement 39,782/hospitalisation; 89,510/patient).CONCLUSION:
Data from this sample of patients suggest that hospitalisations in R/R ALL are lengthy and associated with high costs in Spain.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Health_economic_evaluation
Idioma:
En
Revista:
Pharmacoecon Open
Año:
2019
Tipo del documento:
Article
País de afiliación:
España